{
    "clinical_study": {
        "@rank": "104196", 
        "arm_group": [
            {
                "arm_group_label": "type 2 diabetes", 
                "arm_group_type": "Other", 
                "description": "The standard mixed meal test will be served 30min after intake of sitagliptin 100mg ."
            }, 
            {
                "arm_group_label": "type 2 diabetes without sitagliptin 100mg", 
                "arm_group_type": "Other", 
                "description": "A standard mixed meal test will be served without sitagliptin."
            }
        ], 
        "brief_summary": {
            "textblock": "study hypothesis to examine the acute effects on glycaemia and islet hormone secretion of\n      increased levels of endogenous GLP-1 and GIP on islet cell function in men with type 2\n      diabetes. To this purpose, a standardized mixed meal test will be ingested with or without\n      concomitant administration of sitagliptin (100mg)."
        }, 
        "brief_title": "Effect of a Single Oral Dose DPP-4 Inhibitor Sitagliptin on Islet Function After Intake of a Standardized Mixed Meal in Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "In men subjects with type 2 diabetes treated with diet and exercise with or without\n      metformin treatment as an antidiabetic agent, a standardized mixed meal test will be served\n      with or without administration of sitagliptin (100mg)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Caucasian men with type 2 diabetes diagnosed according to ICD10\n\n          -  Ongoing treatment with life style adjustment or life style adjustment together with\n             metformin as oral antidiabetic. Metformin therapy should not exceed 2 grams daily\n\n          -  Age 20-75 years\n\n          -  HbA1c \u226480 mmol/mol\n\n          -  BMI: 20-40 kg/m2\n\n        Exclusion Criteria:\n\n          -  Liver disease or ALAT three times above upper reference range\n\n          -  Diabetic nephropathy (GFR < 50 mL/min/1.73 m2 or albuminuria)\n\n          -  Proliferative diabetic retinopathy\n\n          -  Treatment with any glucose-lowering medication except metformin\n\n          -  Previous myocardial infarction, coronary heart disease or insatiable angina pectoris\n             in the last 6 months.\n\n          -  Previous surgery on the gastrointestinal tract\n\n          -  Larger surgical intervention during the last 12 weeks\n\n          -  Treatment with oral steroids or thiazide diuretics\n\n          -  Treatment with digoxin\n\n          -  Smokers\n\n          -  Participation in another study the last 4 weeks\n\n          -  Paracetamol intolerance"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01901861", 
            "org_study_id": "2012-005660-98"
        }, 
        "intervention": {
            "arm_group_label": [
                "type 2 diabetes", 
                "type 2 diabetes without sitagliptin 100mg"
            ], 
            "intervention_name": "Sitagliptin 100mg", 
            "intervention_type": "Other", 
            "other_name": "Mixed meal test"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gastric Inhibitory Polypeptide", 
                "Sitagliptin", 
                "Dipeptidyl-Peptidase IV Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "glucagon-like peptide-1 (GLP-1),glucose-dependent insulinotropic polypeptide(GIP), dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors)", 
        "lastchanged_date": "July 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lund", 
                    "country": "Sweden"
                }, 
                "name": "Department of Clinical Science Lund,Lund University"
            }
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Lund University", 
            "last_name": "Bo Ahren, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Release of incretins hormones", 
            "safety_issue": "No", 
            "time_frame": "300 min"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01901861"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Lund University", 
            "investigator_full_name": "Bo Ahren", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Lund University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lund University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}